(Q37880074)

24 August 2017

1 reference

title

From cell biology to therapy: ENMD-2076 in the treatment of multiple myeloma (English)

1 reference

24 August 2017

1 reference

Shuhong Zhang

1

1 reference

24 August 2017

Sherif S Farag

series ordinal

2

1 reference

24 August 2017

language of work or name

English

0 references

publication date

26 May 2011

1 reference

Expert Opinion on Investigational Drugs

24 August 2017

1 reference

24 August 2017

20

1 reference

24 August 2017

7

1 reference

24 August 2017

1015-1028

1 reference

VAD-based regimens as primary treatment for multiple myeloma

24 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.584869

Long-term survival of stage I multiple myeloma given chemotherapy just after diagnosis or at progression of the disease: a multicentre randomized study. Cooperative Group of Study and Treatment of Multiple Myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.584869

High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.584869

Single versus double autologous stem-cell transplantation for multiple myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.584869

Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.584869

The malignant clone and the bone-marrow environment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.584869

Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.584869

Multicenter, randomized, double-blind, placebo-controlled study of thalidomide plus dexamethasone compared with dexamethasone as initial therapy for newly diagnosed multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.584869

Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.584869

Oral melphalan, prednisone, and thalidomide in elderly patients with multiple myeloma: updated results of a randomized controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.584869

Treatment of relapsed and refractory multiple myeloma in the era of novel agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.584869

How best to use new therapies in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.584869

Multiple myeloma: biology of the disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.584869

Advances in biology of multiple myeloma: clinical applications

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.584869

Emerging treatments for multiple myeloma: beyond immunomodulatory drugs and bortezomib

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.584869

Kinome-wide RNAi studies in human multiple myeloma identify vulnerable kinase targets, including a lymphoid-restricted kinase, GRK6.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.584869

Preclinical activity of a novel multiple tyrosine kinase and aurora kinase inhibitor, ENMD-2076, against multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.584869

Assessment of the in vivo antitumor effects of ENMD-2076, a novel multitargeted kinase inhibitor, against primary and cell line-derived human colorectal cancer xenograft models

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.584869

Response rate, durability of response, and survival after thalidomide therapy for relapsed multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.584869

Cytokines and signal transduction

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.584869

Serum levels of interleukin 6, a potent myeloma cell growth factor, as a reflect of disease severity in plasma cell dyscrasias

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.584869

Mechanisms of myeloma cell growth control

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.584869

Interleukin-6-type cytokine signalling through the gp130/Jak/STAT pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.584869

Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.584869

PTEN, but not SHIP and SHIP2, suppresses the PI3K/Akt pathway and induces growth inhibition and apoptosis of myeloma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.584869

Antisense strategy shows that Mcl-1 rather than Bcl-2 or Bcl-x(L) is an essential survival protein of human myeloma cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.584869

The phosphatidylinositol 3-Kinase AKT pathway in human cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.584869

Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.584869

A Phase I-II trial of polyethylene glycol-conjugated L-asparaginase in patients with multiple myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.584869

NF-kappa B as a therapeutic target in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.584869

Inhibition of the insulin-like growth factor receptor-1 tyrosine kinase activity as a therapeutic strategy for multiple myeloma, other hematologic malignancies, and solid tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.584869

Insulinlike growth factor-I signaling in multiple myeloma: downstream elements, functional correlates, and pathway cross-talk

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.584869

Inhibitor of apoptosis proteins: translating basic knowledge into clinical practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.584869

GW654652, the pan-inhibitor of VEGF receptors, blocks the growth and migration of multiple myeloma cells in the bone marrow microenvironment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.584869

VEGF(165) promotes survival of leukemic cells by Hsp90-mediated induction of Bcl-2 expression and apoptosis inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.584869

VEGF induces Mcl-1 up-regulation and protects multiple myeloma cells against apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.584869

Paracrine interactions of basic fibroblast growth factor and interleukin-6 in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.584869

Activated fibroblast growth factor receptor 3 is an oncogene that contributes to tumor progression in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.584869

Frequent translocation t(4;14)(p16.3;q32.3) in multiple myeloma is associated with increased expression and activating mutations of fibroblast growth factor receptor 3

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.584869

The centrosome index is a powerful prognostic marker in myeloma and identifies a cohort of patients that might benefit from aurora kinase inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.584869

Signal transduction pathway of human fibroblast growth factor receptor 3. Identification of a novel 66-kDa phosphoprotein

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.584869

Transformation and Stat activation by derivatives of FGFR1, FGFR3, and FGFR4

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.584869

Preclinical studies of fibroblast growth factor receptor 3 as a therapeutic target in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.584869

Mitotic mechanics: the auroras come into view

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.584869

The Aurora kinases: role in cell transformation and tumorigenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.584869

Aurora kinases as anticancer drug targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.584869

Aurora-A and an interacting activator, the LIM protein Ajuba, are required for mitotic commitment in human cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.584869

CDC25B phosphorylation by Aurora-A occurs at the G2/M transition and is inhibited by DNA damage.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.584869

Uncoupling the central spindle-associated function of the chromosomal passenger complex from its role at centromeres

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.584869

Aurora kinases as targets for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.584869

Antitumor activity of MLN8054, an orally active small-molecule inhibitor of Aurora A kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.584869

Genetics and cytogenetics of multiple myeloma: a workshop report.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.584869

Inhibition of aurora kinases for tailored risk-adapted treatment of multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.584869

The Bcl-2 protein family: arbiters of cell survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.584869

The anti-apoptosis function of Bcl-2 can be genetically separated from its inhibitory effect on cell cycle entry

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.584869

The imbalance between Bim and Mcl-1 expression controls the survival of human myeloma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.584869

Activation of NF-kappaB and upregulation of intracellular anti-apoptotic proteins via the IGF-1/Akt signaling in human multiple myeloma cells: therapeutic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.584869

IAP family protein expression correlates with poor outcome of multiple myeloma patients in association with chemotherapy-induced overexpression of multidrug resistance genes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.584869

Targeting the phosphatidylinositol 3-kinase pathway in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.584869

Growth factor withdrawal and apoptosis: the middle game

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.584869

Serine phosphorylation and maximal activation of STAT3 during CNTF signaling is mediated by the rapamycin target mTOR

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.584869

The small molecule Hesperadin reveals a role for Aurora B in correcting kinetochore-microtubule attachment and in maintaining the spindle assembly checkpoint

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.584869

Exploring the functional interactions between Aurora B, INCENP, and survivin in mitosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.584869

Aurora kinases link chromosome segregation and cell division to cancer susceptibility

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.584869

Aurora A kinase RNAi and small molecule inhibition of Aurora kinases with VE-465 induce apoptotic death in multiple myeloma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.584869

The selective Aurora B kinase inhibitor AZD1152 is a potential new treatment for multiple myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.584869

In vitro anti-myeloma activity of the Aurora kinase inhibitor VE-465.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.584869

A novel Aurora-A kinase inhibitor MLN8237 induces cytotoxicity and cell-cycle arrest in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.584869

Vascular endothelial growth factor inhibition is not an effective therapeutic strategy for relapsed or refractory multiple myeloma: a phase 2 study of pazopanib (GW786034).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.584869

Phase II study of SU5416, a small molecule vascular endothelial growth factor tyrosine kinase receptor inhibitor, in patients with refractory multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.584869

10.1517/13543784.2011.584869

21 January 2018

Identifiers

DOI

1 reference

release_wzgl67azebcqrjxli3kzgtrjo4

24 August 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/wzgl67azebcqrjxli3kzgtrjo4

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference